Results 131 to 140 of about 2,218,427 (310)

Using Zebrafish for Screening and Development of New Nicotinic and Dopaminergic Drugs

, 2012
R. Thomas Boyd
openalex   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Priorities for local immunotherapy research and drug development. [PDF]

J Immunother Cancer
Isaacs JM, Luke J.
europepmc   +1 more source

Mammalian Cell Line Development Platform for Recombinant Protein Production: Expanding the Protein Expression Toolbox for Research and Drug Discovery Applications

, 2017
Elizabeth Del Greco
openalex   +2 more sources

The return of the prodigal son and the extraordinary development route of antibody TGN1412 ‐ lessons for drug development and clinical pharmacology [PDF]

, 2015
Marcel Kenter, Adam F. Cohen
openalex   +1 more source

Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

, 2023
Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet‐Loiseau, Ann T. Farrell, Nicole Gormley, Shaji Kumar, Ola Landgren, Nikhil C. Munshi, Michèle Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James Omel, Trevor J. Pugh, Gregory H. Reaman, Michael Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni   +29 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Dreaming of a better future: drug development in myeloma. [PDF]

Blood Adv
Parikh R, Lonial S.
europepmc   +1 more source

Novel antimalarial drug development

, 2011

openalex   +1 more source

Supplementary Figure S3 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment

, 2023
Prathap Nagaraja Shastri, Jingjing Zhu, Lillian Skidmore, Xuejun Liang, Yanping Ji, Yi Gu, Feng Tian, Sulan Yao, Gang Xia   +8 more
openalex   +1 more source